Calpain as a Therapeutic Target for Hypoxic-Ischemic Encephalopathy

Mol Neurobiol. 2024 Jan;61(1):533-540. doi: 10.1007/s12035-023-03594-3. Epub 2023 Aug 29.

Abstract

Hypoxic-ischemic encephalopathy (HIE) is a complex pathophysiological process with multiple links and factors. It involves the interaction of inflammation, oxidative stress, and glucose metabolism, and results in acute and even long-term brain damage and impairment of brain function. Calpain is a family of Ca2+-dependent cysteine proteases that regulate cellular function. Calpain activation is involved in cerebral ischemic injury, and this involvement is achieved by the interaction among Ca2+, substrates, organelles, and multiple proteases in the neuronal necrosis and apoptosis pathways after cerebral ischemia. Many calpain inhibitors have been developed and tested in the biochemical and biomedical fields. This study reviewed the potential role of calpain in the treatment of HIE and related mechanism, providing new insights for future research on HIE.

Keywords: Calpain; Calpastatin; HET0016; Hypoxic-ischemic encephalopathy; Mechanism.

Publication types

  • Review

MeSH terms

  • Calpain / metabolism
  • Cerebral Infarction / drug therapy
  • Humans
  • Hypoxia-Ischemia, Brain* / drug therapy
  • Hypoxia-Ischemia, Brain* / metabolism
  • Necrosis / drug therapy

Substances

  • Calpain